{"doi":"10.1016/j.pbb.2013.09.006","title":"Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats","abstract":null,"journal":"Pharmacology Biochemistry and Behavior","year":2013,"id":667657,"datarank":0.42498200160843247,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.0,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":237880,"name":"Guangrong Zheng","orcid":"0000-0002-8106-6663","position":1,"is_corresponding":false},{"id":414591,"name":"Peter A. Crooks","orcid":"0000-0002-1312-6150","position":2,"is_corresponding":false},{"id":514369,"name":"Linda P. Dwoskin","orcid":null,"position":3,"is_corresponding":false},{"id":185278,"name":"Michael T. Bardo","orcid":null,"position":4,"is_corresponding":false},{"id":1743532,"name":"Carrie E. Wilmouth","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats","abstract":"Despite the high prevalence of use of methamphetamine (METH), there is no FDA-approved pharmacological treatment available currently for METH addiction. The vesicular monoamine transporter (VMAT2) has been proposed as a novel target to treat METH abuse. GZ-793A, a lobelane analog and selective VMAT2 inhibitor, has been shown previously to decrease METH self-administration specifically when administered via the subcutaneous route in rats. Since oral administration is the preferred clinical route, the present experiments determined if oral administration of GZ-793A would decrease specifically METH self-administration. Experiments 1 and 2 assessed the dose-effect functions of oral administration of GZ-793A (30-240 mg/kg) on intravenous METH self-administration and food-maintained responding, respectively. Experiments 3 and 4 assessed the time-course (20-180 min pretreatment) of oral administration of GZ-793A on METH self-administration and food-maintained responding, respectively. Oral administration of GZ-793A dose-dependently decreased METH self-administration, with the highest dose (240 mg/kg) producing an 85% decrease compared to control baseline. The decrease in METH self-administration produced by GZ-793A (120 mg/kg) lasted at least 180 min. In contrast, GZ-793A failed to alter food-maintained responding at any of the doses or pretreatment intervals tested. The oral effectiveness and the specificity of GZ-793A to decrease methamphetamine self-administration support the feasibility of developing VMAT2 inhibitors as treatments for METH abuse.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24075974","pmcid":"PMC3842023","openalex_id":null,"authors":[],"funders":[{"funder_name":"NIH","grant_id":"U01 DA13519","title":null},{"funder_name":"NIH","grant_id":"T32 DA01617","title":null},{"funder_name":"NIDA NIH HHS","grant_id":"T32 DA016176","title":null},{"funder_name":"NIDA NIH HHS","grant_id":"U01 DA013519","title":null}],"total_grants":4,"fwci":null,"citation_percentile":null,"influential_citations":1,"citation_trend":[],"oa_status":"green","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://europepmc.org/articles/pmc3842023?pdf=render","host_type":"GREEN"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3842023","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S0091305713002220?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0091305713002220?httpAccept=text/plain","host_type":"publisher"}],"fields_of_study":["Medicine","Psychology"],"mesh_terms":["Animals","Rats","Rats, Sprague-Dawley","Methamphetamine","Lobeline","Self Administration","Administration, Oral","Dose-Response Relationship, Drug","Male","Vesicular Monoamine Transport Proteins"],"keywords":["Dopamine","VMAT2","methamphetamine","Self-administration"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-13T18:37:06.249381Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}